Psoriasis, Folic Acid Supplementation and Plasma Homocysteine Levels

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002306-29-GB

Enrollment

Registered

2005-02-17

Start date

2004-12-21

Completion date

Unknown

Last updated

2012-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Trade Name: Folic acid tablet BP 5mg Product Name: Folic acid Pharmaceutical Form: Capsule* INN or Proposed INN: Folic acid CAS Number: 129025-21-4 Concentration unit: mg milligram(s) Concentration ty

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Psoriasis On or suitable for methotrexate therapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Under 18 years of age Over 65 years of age On vitamin B12 supplements

Design outcomes

Primary

Measure	Time frame
Main Objective: To find out if folic acid supplementation reduces plasma homocysteine levels in psoriatic patients taking methotrexate ;Secondary Objective: To see if folic acid supplementation has any effect on the efficacy of methotrexate in psoriasis;Primary end point(s): Completion of 12 weeks	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026